← Back to Search

High Protein Diet + Exercise for Muscle Loss (PROXIMUS Trial)

Boston, MA
N/A
Recruiting
Led By Nilesh Mehta, MD
Research Sponsored by Boston Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
PICU patients aged 1 year (corrected) to <18 years
Require mechanical ventilation (endotracheal intubation or tracheostomy) in the first 48 hours of PICU admission, and are expected to remain intubated for ≥48 hours
Must not have
Kidney failure (≥KDIGO Stage 3) without replacement therapy
Inborn errors of metabolism
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a high protein diet and individualized exercise plan can help preserve muscle mass and improve function in children during the acute phase of critical illness.

See full description
Who is the study for?
This trial is for children aged 1 to under 18 years who are on mechanical ventilation within the first 48 hours of PICU admission and expected to stay on it. They must be able to consent within this period. It's not for those with liver failure, certain medical conditions requiring bedrest, high-risk burns, severe kidney issues without therapy, or incompatible diets.Check my eligibility
What is being tested?
The PROXIMUS study tests if giving high protein with tailored exercise during critical illness helps maintain muscle mass and improve mobility in kids after treatment. Participants will either receive this new approach or standard care, decided randomly at two centers.See study design
What are the potential side effects?
Potential side effects may include digestive discomfort due to high protein intake and physical strain from exercise routines. However, the main focus is on feasibility and safety so close monitoring will occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 1 and 17 years old, corrected for prematurity.
 show original
Select...
I needed a breathing tube within the first 48 hours of ICU admission and will need it for at least 2 more days.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidney function is severely reduced and I am not on dialysis.
 show original
Select...
I have a genetic disorder that affects my metabolism.
 show original
Select...
I have severe burns covering a large part of my body.
 show original
Select...
I am receiving or have received ECMO therapy.
 show original
Select...
I am experiencing severe liver failure.
 show original
Select...
I need to be in bed or have muscle relaxants for medical reasons.
 show original
Select...
My child was fairly active when admitted to the PICU.
 show original
Select...
I cannot receive standard nutrition support or follow the study's diet.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility of recruitment and adherence to study procedures
Safety of protein (new renal injury) and exercise interventions (any associated adverse events)
Tolerability of protein intervention (serum creatinine change)
Secondary study objectives
Assessment of Functional status - sensory, communication, motor, sensory and feeding
Change in Muscle mass thickness
Functional assessment - motor, cognitive and responsibility
+1 more
Other study objectives
Protein catabolism (breakdown)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: High protein plus exerciseExperimental Treatment1 Intervention
High protein nutrition: To achieve the prescribed age-appropriate high protein target, dietitians will use EN preferentially, or if EN is contraindicated, PN may be used. High-protein EN formulas and/or protein supplements (powder or liquid) will be added to formula/breast milk feedings or administered separately in divided bolus doses. Dietitians routinely employ and customize these solutions in their scope of practice. When EN is insufficient to meet protein targets, PN may be prescribed to make up the deficit on or after the end of PICU day 3. Energy and protein delivery adequacy (% of prescribed goal) will be monitored daily by the study team. Patients in this arm will also be prescribed the age-appropriate highest-level of mobility by the rehabilitation team with a goal of 30 minutes duration, twice daily.
Group II: Standard protein and exerciseActive Control1 Intervention
All enrolled patients randomized to this arm will receive a baseline nutrition and nurse-driven mobility pathway and other evidence-based bundled strategies as standard of care.

Find a Location

Closest Location:Johns Hopkins Hospital· Baltimore, MD· 344 miles

Who is running the clinical trial?

Boston Children's HospitalLead Sponsor
795 Previous Clinical Trials
5,583,612 Total Patients Enrolled
Johns Hopkins UniversityOTHER
2,361 Previous Clinical Trials
15,160,410 Total Patients Enrolled
Nilesh Mehta, MDPrincipal InvestigatorFaculty, Boston Children's Hospital
Sapna R Kudchadkar, MD, PhDPrincipal InvestigatorFaculty, Johns Hopkins
1 Previous Clinical Trials
2,500 Total Patients Enrolled

Media Library

Protein dosage and rehabilitation team delivered exercise prescription Clinical Trial Eligibility Overview. Trial Name: NCT05296096 — N/A
Muscle Atrophy Research Study Groups: Standard protein and exercise, High protein plus exercise
Muscle Atrophy Clinical Trial 2023: Protein dosage and rehabilitation team delivered exercise prescription Highlights & Side Effects. Trial Name: NCT05296096 — N/A
Protein dosage and rehabilitation team delivered exercise prescription 2023 Treatment Timeline for Medical Study. Trial Name: NCT05296096 — N/A
~17 spots leftby Dec 2025